-The Indian Express Drug regulation is a mess. Everyone who propped up this irresponsible system is to blame Last week, a parliamentary standing committee on health delivered a thoroughly damaging report on the state of drug regulation in India, and the collusion between the regulator, industry and the medical profession that puts patients last. Over 118 pages, it said that the Drug Controller General of India (DCGI) and the Drug Standards Control...
More »SEARCH RESULT
Probe into alleged doctors-pharma firms' connivance sought-Aarti Dhar
Health activists from across the country have asked the Union Health and Family Welfare Ministry to take immediate cognisance of the recent report of the Department Related Standing Committee that has criticised the functioning of the Central Drugs Standard Control Organisation (CDSCO) for irregular approvals for clinical trials and sale of medicines to pharmaceutical companies that put patients at risk. In a statement issued here on Wednesday, the activists asked the...
More »Indians popping more antibiotics than ever: Study-Kounteya Sinha
There has been a six-fold increase in the number of antibiotics being popped by Indians. This includes the retail sale of Carbapenems -- powerful class IV antibiotics, typically used as a "last resort" to treat serious infections caused by multi-drug resistant, gram-negative pathogens. Research by the Centre for Disease Dynamics, Economics and Policy, Washington DC, has found that retail sale of carbapenems increased six times -- from 0.21 units per million...
More »The government needs to think out of the box to help pharma grow while keeping medicines affordable-Ramesh Adige
Having watched from the ringside for many years now, I have no doubt in advising that the steering wheel must be firmly grasped by the government and direction given to policies that should be stable for at least the medium term. This is crucial for the growth of Indian pharma, a $20-billion industry growing at an average of 12% considering both domestic and export arenas. Price control: The biggest and most...
More »Panel exposes flaws in India’s drug approval procedure-Vidya Krishnan
A report by a parliamentary committee has shown that the drug industry regulator, the Drug Controller General of India (DCGI), has been approving, on average, one new drug a month without conducting mandatory clinical trials or seeking expert medical opinion—findings that expose the deep flaws prevalent in India’s drug approval process. The committee has asked the health ministry to withdraw the discretionary powers given to the Central Drugs Standard Control Organization...
More »